PMID- 30728405
OWN - NLM
STAT- MEDLINE
DCOM- 20200819
LR  - 20200819
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 Feb 6
TI  - Differential expression of CXCR3 and CCR6 on CD4(+) T-lymphocytes with distinct 
      memory phenotypes characterizes tuberculosis-associated immune reconstitution 
      inflammatory syndrome.
PG  - 1502
LID - 10.1038/s41598-018-37846-3 [doi]
LID - 1502
AB  - Immune reconstitution inflammatory syndrome (IRIS) occurs in up to 40% of 
      individuals co-infected with pulmonary tuberculosis (PTB) and HIV, primarily upon 
      antiretroviral therapy (ART) initiation. Phenotypic changes in T-cells during 
      TB-IRIS and their relationship with systemic inflammation are not fully 
      understood. In this prospective cohort study, we followed 48 HIV-positive 
      patients with PTB from South India before and after ART initiation, examining 
      T-lymphocyte subsets and inflammatory biomarkers in peripheral blood. 
      Quantification of naive (CD27(+)CD45RO(-)) as well as effector memory CD4(+) T 
      cells (CD27(-)CD45RO(+)) at weeks 2-6 after ART initiation could distinguish 
      TB-IRIS from non-IRIS individuals. Additional analyses revealed that ART 
      reconstituted different quantities of CD4(+) T lymphocyte subsets with 
      preferential expansion of CXCR3(+) CCR6(-) cells in TB-IRIS patients. Moreover, 
      there was an expansion and functional restoration of central memory 
      (CD27(+)CD45RO(+)) CXCR3(+)CCR6(-) CD4(+) lymphocytes and corresponding 
      cytokines, with reduction in CXCR3(-)CCR6(+) cells after ART initiation only in 
      those who developed TB-IRIS. Together, these observations trace a detailed 
      picture of CD4(+) T cell subsets tightly associated with IRIS, which may serve as 
      targets for prophylactic and/or therapeutic interventions in the future.
FAU - Silveira-Mattos, Paulo S
AU  - Silveira-Mattos PS
AD  - Instituto Goncalo Moniz, Salvador, Bahia, Brazil.
AD  - Multinational Organization Network Sponsoring Translational and Epidemiological 
      Research (MONSTER) Initiative, Fundacao Jose Silveira, Salvador, Bahia, Brazil.
FAU - Narendran, Gopalan
AU  - Narendran G
AUID- ORCID: 0000-0002-8049-7541
AD  - National Institute for Research in Tuberculosis, Chennai, India.
FAU - Akrami, Kevan
AU  - Akrami K
AD  - Instituto Goncalo Moniz, Salvador, Bahia, Brazil.
AD  - Division of Infectious Diseases, Department of Medicine, University of 
      California, San Diego, United States of America.
FAU - Fukutani, Kiyoshi F
AU  - Fukutani KF
AUID- ORCID: 0000-0003-2223-0918
AD  - Instituto Goncalo Moniz, Salvador, Bahia, Brazil.
AD  - Multinational Organization Network Sponsoring Translational and Epidemiological 
      Research (MONSTER) Initiative, Fundacao Jose Silveira, Salvador, Bahia, Brazil.
FAU - Anbalagan, Selvaraj
AU  - Anbalagan S
AD  - National Institute for Research in Tuberculosis, Chennai, India.
FAU - Nayak, Kaustuv
AU  - Nayak K
AD  - National Institute for Research in Tuberculosis, Chennai, India.
FAU - Subramanyam, Sudha
AU  - Subramanyam S
AD  - National Institute for Research in Tuberculosis, Chennai, India.
FAU - Subramani, Rajasekaran
AU  - Subramani R
AD  - National Institute for Research in Tuberculosis, Chennai, India.
FAU - Vinhaes, Caian L
AU  - Vinhaes CL
AD  - Instituto Goncalo Moniz, Salvador, Bahia, Brazil.
AD  - Multinational Organization Network Sponsoring Translational and Epidemiological 
      Research (MONSTER) Initiative, Fundacao Jose Silveira, Salvador, Bahia, Brazil.
FAU - Souza, Deivide Oliveira-de
AU  - Souza DO
AD  - Instituto Goncalo Moniz, Salvador, Bahia, Brazil.
AD  - Multinational Organization Network Sponsoring Translational and Epidemiological 
      Research (MONSTER) Initiative, Fundacao Jose Silveira, Salvador, Bahia, Brazil.
FAU - Antonelli, Lis R
AU  - Antonelli LR
AD  - Laboratorio de Biologia e Imunologia de Doencas Infecciosas e Parasitarias, 
      Instituto Rene Rachou, Fundacao Oswaldo Cruz, Belo Horizonte, Minas Gerais, 
      Brazil.
FAU - Satagopan, Kumar
AU  - Satagopan K
AD  - Government Hospital of Thoracic Medicine, Tambaram, Chennai, India.
FAU - Porter, Brian O
AU  - Porter BO
AD  - Clinical HIV Pathogenesis Section, Laboratory of Immunoregulation, National 
      Institute of Allergy and Infectious Diseases, National Institutes of Health, 
      Bethesda, Maryland, United States of America.
FAU - Sher, Alan
AU  - Sher A
AD  - Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of 
      Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 
      Maryland, United States of America.
FAU - Swaminathan, Soumya
AU  - Swaminathan S
AD  - National Institute for Research in Tuberculosis, Chennai, India.
FAU - Sereti, Irini
AU  - Sereti I
AD  - Clinical HIV Pathogenesis Section, Laboratory of Immunoregulation, National 
      Institute of Allergy and Infectious Diseases, National Institutes of Health, 
      Bethesda, Maryland, United States of America.
FAU - Andrade, Bruno B
AU  - Andrade BB
AUID- ORCID: 0000-0001-6833-3811
AD  - Instituto Goncalo Moniz, Salvador, Bahia, Brazil. bruno.andrade@fiocruz.br.
AD  - Multinational Organization Network Sponsoring Translational and Epidemiological 
      Research (MONSTER) Initiative, Fundacao Jose Silveira, Salvador, Bahia, Brazil. 
      bruno.andrade@fiocruz.br.
AD  - Wellcome Trust Centre for Infectious Disease Research in Africa, Institute of 
      Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, 
      Republic of South Africa. bruno.andrade@fiocruz.br.
AD  - Escola Bahiana de Medicina e Saude Publica (EBMSP), Salvador, Bahia, Brazil. 
      bruno.andrade@fiocruz.br.
AD  - Universidade Salvador (UNIFACS), Laureate Universities, Salvador, Bahia, Brazil. 
      bruno.andrade@fiocruz.br.
AD  - Division of Infectious Diseases, Department of Medicine, Vanderbilt University 
      School of Medicine, Nashville, Tennessee, United States of America. 
      bruno.andrade@fiocruz.br.
LA  - eng
GR  - U01 AI115940/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190206
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (CCR6 protein, human)
RN  - 0 (CXCR3 protein, human)
RN  - 0 (Receptors, CCR6)
RN  - 0 (Receptors, CXCR3)
SB  - IM
EIN - Sci Rep. 2019 May 24;9(1):8036. PMID: 31123316
MH  - Adult
MH  - Aged
MH  - Anti-Retroviral Agents/administration & dosage/adverse effects/immunology
MH  - CD4-Positive T-Lymphocytes/*immunology/metabolism
MH  - Cohort Studies
MH  - Coinfection/immunology/parasitology/virology
MH  - Female
MH  - HIV Infections/drug therapy/*immunology/parasitology
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/chemically induced/*immunology
MH  - Immunologic Memory/drug effects
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Receptors, CCR6/biosynthesis/genetics/*immunology
MH  - Receptors, CXCR3/*biosynthesis/genetics/*immunology
MH  - T-Lymphocyte Subsets/drug effects/immunology
MH  - Tuberculosis, Pulmonary/drug therapy/*immunology/virology
PMC - PMC6365576
COIS- The authors declare no competing interests.
EDAT- 2019/02/08 06:00
MHDA- 2020/08/20 06:00
PMCR- 2019/02/06
CRDT- 2019/02/08 06:00
PHST- 2018/10/05 00:00 [received]
PHST- 2018/12/12 00:00 [accepted]
PHST- 2019/02/08 06:00 [entrez]
PHST- 2019/02/08 06:00 [pubmed]
PHST- 2020/08/20 06:00 [medline]
PHST- 2019/02/06 00:00 [pmc-release]
AID - 10.1038/s41598-018-37846-3 [pii]
AID - 37846 [pii]
AID - 10.1038/s41598-018-37846-3 [doi]
PST - epublish
SO  - Sci Rep. 2019 Feb 6;9(1):1502. doi: 10.1038/s41598-018-37846-3.